TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress
19th Feb 2024 18:57
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve. Read More
Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
Genedrive PLC - Manchester, England-based molecular diagnostics company - Says initial orders of its MT-RNR1 products from France, Austria, the Netherlands, Greece, Saudi Arabia and Turkey have been received. News follows confirmation that commercial distribution agreements were signed in multiple countries for Genedrive's test for antibiotic induced hearing loss. Genedrive says these initial orders will support its international distribution partners in promotion and in-country evaluation activities in their respective countries. Hopes this will "provide more extensive access to this life-changing test." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Genedrive PLC on Thursday reported a widened loss but said it remains focused on investing in product development, focusing on maximising the benefits of its platform. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Genedrive PLC - Manchester-based molecular diagnostics company - Confirms that it expects to benefit from GBP1.2 million of funding, through its participation in a multi-partner grant award from Innovate UK and the UK government Innovation Accelerator programme. The grant, which is for the development and validation of technology for time critical genomic testing, will provide Genedrive with acute care patient access and supporting infrastructure to assess the real world clinical performance of time-critical clinical tests in NHS settings. Read More
(Alliance News) - Genedrive PLC on Monday said it appointed James Cheek as its new chief executive officer, effective immediately. Read More
(Alliance News) - Genedrive PLC on Wednesday said that its CYP2C19 point of care test achieved marking registration in the UK, known as UKCA. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a multi-partner grant for the validation of its CYP2X19 ID kit from Innovate UK and the UK government Innovation Accelerator programme. Says the 'Devote' grant will allow it to offer critical clinical tests in NHS settings. Read More
(Alliance News) - Genedrive PLC on Friday said draft guidance from the UK's National Institute for Health & Care Excellence has recommended that CYP2C19 genotyping should be used to manage ischemic stroke patients. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Reports revenue in the six months to December 31 of GBP20,000 compared to nothing a year prior, and an operating loss of GBP2.7 million from GBP2.8 million. Confident that the company will see an acceleration of revenues through 2023 and going forwards. Agrees GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd with an initial drawn amount of GBP2 million, expected to be received in early April. Proceeds will be used towards the commercialisation of the antibiotic induced hearing loss test, Genedrive MT-RNR1 ID Kit and enhancing the Genedrive platform as well as providing additional working capital. Directors believe the facility is the best option available at present. Read More